Parker L - Search Results

1

Changes in the type and amount of spending disclosed by Australian pharmaceutical companies: an observational study.

Parker L, Karanges EA, Bero L. Parker L, et al. BMJ Open. 2019 Feb 19;9(2):e024928. doi: 10.1136/bmjopen-2018-024928. BMJ Open. 2019. PMID: 30782921 Free PMC article.

2

Ethical drug marketing criteria for the 21st century.

Parker L, Williams J, Bero L. Parker L, et al. BMJ. 2018 Apr 30;361:k1809. doi: 10.1136/bmj.k1809. BMJ. 2018. PMID: 29712644 Review. No abstract available.

3

Interpreting evidence in general practice: Bias and conflicts of interest.

Parker L, Grundy Q, Bero L. Parker L, et al. Aust J Gen Pract. 2018 Jun;47(6):337-340. doi: 10.31128/AJGP-12-17-4432. Aust J Gen Pract. 2018. PMID: 29966180 Free article.

4

Mental Health Messages in Prominent Mental Health Apps.

Parker L, Bero L, Gillies D, Raven M, Mintzes B, Jureidini J, Grundy Q. Parker L, et al. Ann Fam Med. 2018 Jul;16(4):338-342. doi: 10.1370/afm.2260. Ann Fam Med. 2018. PMID: 29987082 Free PMC article.

5

Medical donations are not always free: an assessment of compliance of medicine and medical device donations with World Health Organization guidelines (2009-2017).

McDonald S, Fabbri A, Parker L, Williams J, Bero L. McDonald S, et al. Among authors: parker l. Int Health. 2019 Sep 2;11(5):379-402. doi: 10.1093/inthealth/ihz004. Int Health. 2019. PMID: 30916303

6

The "Hot Potato" of Mental Health App Regulation: A Critical Case Study of the Australian Policy Arena.

Parker L, Bero L, Gillies D, Raven M, Grundy Q. Parker L, et al. Int J Health Policy Manag. 2019 Mar 1;8(3):168-176. doi: 10.15171/ijhpm.2018.117. Int J Health Policy Manag. 2019. PMID: 30980633 Free PMC article.

7

Health promoter, advocate, legitimiser - the many roles of WHO guidelines: a qualitative study.

Wang Z, Grundy Q, Parker L, Bero L. Wang Z, et al. Among authors: parker l. Health Res Policy Syst. 2019 Dec 5;17(1):96. doi: 10.1186/s12961-019-0489-z. Health Res Policy Syst. 2019. PMID: 31805956 Free PMC article.

8

"Asset exchange"-interactions between patient groups and pharmaceutical industry: Australian qualitative study.

Parker L, Fabbri A, Grundy Q, Mintzes B, Bero L. Parker L, et al. BMJ. 2019 Dec 12;367:l6694. doi: 10.1136/bmj.l6694. BMJ. 2019. PMID: 31831471 Free PMC article.

9

Industry funding of patient and health consumer organisations: systematic review with meta-analysis.

Fabbri A, Parker L, Colombo C, Mosconi P, Barbara G, Frattaruolo MP, Lau E, Kroeger CM, Lunny C, Salzwedel DM, Mintzes B. Fabbri A, et al. Among authors: parker l. BMJ. 2020 Jan 22;368:l6925. doi: 10.1136/bmj.l6925. BMJ. 2020. PMID: 31969320 Free PMC article.

10

Pharmaceutical industry payments to leaders of professional medical associations in Australia: Focus on cardiovascular disease and diabetes.

Karanges EA, Ting N, Parker L, Fabbri A, Bero L. Karanges EA, et al. Among authors: parker l. Aust J Gen Pract. 2020 Mar;49(3):151-154. doi: 10.31128/AJGP-08-19-5041. Aust J Gen Pract. 2020. PMID: 32113215 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,147 results

Search Page

Filters